You are here

Our science / Clinical Trials / Find a Trial / NCT00448032

Study Evaluating Multiple Oral Doses of PPM-204 in Healthy Japanese Male Subjects

Back to Search Print Save as PDF Bookmark Trial

NCT00448032

Last updated on May 10, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Tokyo, , 171-0014 Japan
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Diabetes Mellitus
Sex
Male
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
20-45 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Men, aged 20 to 45 years, inclusive

- Body mass index in the range of 17.6 to 26.4 kg/m2

- Healthy as determined by the investigator on the basis of medical history, physical
examination, clinical laboratory test results, vital signs, and 12-lead
electrocardiogram (ECG)

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- History of cardiac, thyroid, muscle, and kidney abnormalities

- History of NSAID induced bronchospasm or asthma

- History of any clinically important allergies

NCT00448032
Pfizer
Completed
Study Evaluating Multiple Oral Doses of PPM-204 in Healthy Japanese Male Subjects

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Advanced Search

Similar Trials

Type 1 Diabetes Mellitus
A Study To Assess The Safety Of PF-06342674 In Adults With Type 1 Diabetes
NCT02038764
All Genders
18+
Years
Multiple Sites
Diabetes Mellitus, Type 2 Diabetes Mellitus, Glucose Metabolism Disorders, Metabolic Diseases, Endocrine System Diseases
Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females
NCT01301456
Females
18+
Years
Multiple Sites
Type 2 Diabetes Mellitus
4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes
NCT03538743
All Genders
18+
Years
Multiple Sites
Type 1 Diabetes Mellitus
Safety And Efficacy Of Exubera Compared With Subcutaneous Human Insulin Therapy In Children And Adolescents
NCT00479258
All Genders
6+
Years
Buffalo, New York
Study Evaluating Multiple Oral Doses of PPM-204 in Healthy Japanese Male Subjects
A Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Ppm-204 Administered Orally to Healthy Male Japanese Subjects
A study evaluating the safety and pharmacokinetics of multiple oral doses of an investigational oral diabetic agent when given to healthy Japanese male volunteers.
Not Provided
Interventional
Phase 1
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double
Primary Purpose: Diagnostic
Diabetes Mellitus
Drug: PPM-204
Not Provided
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
March 2007
Not Provided

Inclusion Criteria:

  • Men, aged 20 to 45 years, inclusive
  • Body mass index in the range of 17.6 to 26.4 kg/m2
  • Healthy as determined by the investigator on the basis of medical history, physical examination, clinical laboratory test results, vital signs, and 12-lead electrocardiogram (ECG)

Exclusion Criteria:

  • History of cardiac, thyroid, muscle, and kidney abnormalities
  • History of NSAID induced bronchospasm or asthma
  • History of any clinically important allergies
Sexes Eligible for Study: Male
20 Years to 45 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
Japan
 
 
NCT00448032
3180A1-107
Not Provided
Not Provided
Not Provided
Not Provided
Wyeth is now a wholly owned subsidiary of Pfizer
Not Provided
Study Director: Medical Monitor Wyeth is now a wholly owned subsidiary of Pfizer
Wyeth is now a wholly owned subsidiary of Pfizer
December 2007

ICMJE     Data element required by the

International Committee of Medical Journal Editors and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now